{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:53:45Z","timestamp":1791478425107,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.htct.2026.106494","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:15:05Z","timestamp":1783635305000},"page":"106494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylaxis of graft-versus-host-disease: Systematic evidence-based recommendations of the Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and the Brazilian society of cellular therapy and bone marrow transplantation (SBTMO)"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-1313","authenticated-orcid":false,"given":"Afonso C.","family":"Vigorito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmino A.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaneuza A.M.","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Claudia R.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Seber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Luiz Guerino","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanderley","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando B.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2026.106494_bib0001","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.htct.2026.106494_bib0002","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.htct.2026.106494_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0004","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3389\/fimmu.2019.02319","article-title":"Interleukin-6 as biomarker for acute GvHD and survival after allogeneic transplant with post-transplant cyclophosphamide","volume":"10","author":"Greco","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.htct.2026.106494_bib0005","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute GvHD and for chronic GvHD disease according to NIH consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0006","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GvHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0007","series-title":"Hematology 2008: american society of hematology education program book","first-page":"134","article-title":"Recognizing and managing chronic graft-versus-host disease","author":"Lee","year":"2008"},{"key":"10.1016\/j.htct.2026.106494_bib0008","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.bbmt.2020.08.029","article-title":"A new standard in graft-versus-host disease prophylaxis? An introduction to blood and marrow transplant clinical trials network 1703","volume":"26","author":"DeFilipp","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0009","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2026.106494_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor\u2013free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2026.106494_bib0011","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored Multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2026.106494_bib0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med N Engl J Med"},{"key":"10.1016\/j.htct.2026.106494_bib0013","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.htct.2026.106494_bib0014","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0015","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0016","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","article-title":"A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GvHD prophylaxis in myeloablative allogeneic bone marrow transplantation","volume":"34","author":"Bolwell","year":"2004","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0017","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/bmt.2013.89","article-title":"Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GvHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation","volume":"48","author":"Hamilton","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0018","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/bloodadvances.2023010310","article-title":"Tacrolimus\/methotrexate vs tacrolimus \/reduced-dose methotrexate \/ mycophenolate for graft-versus-host disease prevention","volume":"7","author":"Hamilton","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2026.106494_bib0019","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3324\/haematol.2015.123588","article-title":"Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease","volume":"100","author":"Pidala","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2026.106494_bib0020","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GvHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0021","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2026.106494_bib0022","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.6002\/ect.2020.0004","article-title":"Combination of low-dose, short-course mycophenolate mofetil with cyclosporine and methotrexate for graft-versus-host disease prophylaxis in allogeneic stem cell transplant","volume":"19","author":"Ramzi","year":"2021","journal-title":"Exp Clin Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0023","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/ajh.26320","article-title":"Low- dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor","volume":"96","author":"Cho","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.htct.2026.106494_bib0024","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2026.106494_bib0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2026.106494_bib0026","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0027","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2026.106494_bib0028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2026.106494_bib0029","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2026.106494_bib0030","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00277-022-04990-w","article-title":"Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil","volume":"101","author":"Sakatoku","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2026.106494_bib0031","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbmt.2018.08.018","article-title":"Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation","volume":"25","author":"Chhabra","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0032","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2009.362","article-title":"MTX or mycophenolate mofetil with CsA as GvHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings","volume":"45","author":"Pi\u00f1ana","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0033","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1182\/blood.V128.22.5786.5786","article-title":"Addition of more immunosuppressive drugs as graft-versus-host disease (GvHD) prophylaxis does not improve GvHD outcomes in reduced intensity allogeneic hematopoietic cell transplantation from unrelated donors","volume":"128","author":"Michallet","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0034","first-page":"1025.e1","article-title":"Comparison of three graft-versus-host disease prophylaxis strategies after T cell-replete haploidentical hematopoietic transplantation: tacrolimus versus calcineurin inhibitors + mycophenolate mofetil versus sirolimus + mycophenolate mofetil","volume":"30","author":"Esquirol","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.htct.2026.106494_bib0035","first-page":"229.e1","article-title":"Sirolimus is an acceptable alternative to Tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide","volume":"30","author":"Elmariah","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.htct.2026.106494_bib0036","first-page":"236","article-title":"Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis","volume":"2","author":"Hernani","year":"2021","journal-title":"E J Haem"},{"key":"10.1016\/j.htct.2026.106494_bib0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.htct.2026.106494_bib0038","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2026.106494_bib0039","first-page":"349","article-title":"Comparison of exclusive posttransplant cyclophosphamide versus a calcineurin inhibitor based regimen as GvHD prophylaxis in allogeneic bone marrow transplantation from HLA identical sibling","volume":"55","author":"Barrios","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/bloodadvances.2024014781","article-title":"PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation","volume":"9","author":"Desai","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2026.106494_bib0041","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbmt.2015.08.034","article-title":"Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen\u2013matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies","volume":"22","author":"Jacoby","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0042","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/bloodadvances.2019000236","article-title":"Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GvHD prophylaxis in matched sibling transplantation","volume":"3","author":"Kwon","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2026.106494_bib0043","first-page":"313.e1","article-title":"Impact of post-transplantation cyclophosphamide on transfusion requirements in HLA-matched sibling peripheral blood stem cell transplantation","volume":"29","author":"Marco-Ayala","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.htct.2026.106494_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117071","article-title":"Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients","volume":"491","author":"Sharaf El-Deen","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.htct.2026.106494_bib0045","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41409-025-02610-5","volume":"60","author":"Battipaglia","year":"2025","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0046","first-page":"500.e1","article-title":"Mycophenolate mofetil: a friend or a foe with post-transplantation cyclophosphamide and tacrolimus prophylaxis in HLA-matched donors?","volume":"28","author":"Mehta","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.htct.2026.106494_bib0047","volume":"29","author":"El Jurdi","year":"2023","journal-title":"MedRxiv [Preprint]"},{"issue":"3","key":"10.1016\/j.htct.2026.106494_bib0048","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.13977","article-title":"Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation","volume":"173","author":"Mehta","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.htct.2026.106494_bib0049","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft- versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, Tacrolimus, and mycophenolate mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/ejh.13529","article-title":"Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation","volume":"106","author":"Montoro","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.htct.2026.106494_bib0051","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/ejh.14294","volume":"113","author":"Redondo","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.htct.2026.106494_bib0052","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"Bazarbachi","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.htct.2026.106494_bib0053","first-page":"536.e1","article-title":"Outcomes of antithymocyte globulin-Post-transplantation cyclophosphamide-cyclosporine-based versus antithymocyte globulin-based prophylaxis for 10\/10 HLA-matched unrelated donor allogeneic hematopoietic cell transplantation","volume":"30","author":"Salas","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.htct.2026.106494_bib0054","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41409-022-01816-1","article-title":"Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the acute leukemia working party of the EBMT","volume":"57","author":"Spyridonidis","year":"2022","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12185-021-03280-x","article-title":"Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies","volume":"115","author":"Chen","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.htct.2026.106494_bib0056","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4049\/jimmunol.2000578","article-title":"Posttransplant cyclophosphamide and antithymocyte globulin versus Posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell haploidentical transplants: comparison of T cell and NK effector reconstitution","volume":"205","author":"Makanga","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.htct.2026.106494_bib0057","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clml.2020.04.003","article-title":"Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation","volume":"20","author":"El-Cheikh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.htct.2026.106494_bib0058","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00277-020-04033-2","article-title":"Posttransplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation","volume":"99","author":"Pasic","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2026.106494_bib0059","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720965900","article-title":"Post- transplant cyclophosphamide and thymoglobulin, a graft-versus-host disease prophylaxis in matched sibling donor peripheral blood stem cell transplantations","volume":"29","author":"Kunacheewa","year":"2020","journal-title":"Cell Transpl"},{"key":"10.1016\/j.htct.2026.106494_bib0060","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3324\/haematol.2016.149294","article-title":"A prospective randomized trial comparing cyclosporine\/methotrexate and tacrolimus\/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"T\u00f6rl\u00e9n","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2026.106494_bib0061","first-page":"575.e1","article-title":"Triple-drug graft-versus-host disease prophylaxis after HLA-matched unrelated donor nonmyeloablative allogenic hematopoietic stem cell transplantation","volume":"29","author":"Wegener","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.htct.2026.106494_bib0062","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood.2020005338","article-title":"Sirolimus with CSP and MMF as GvHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors","volume":"136","author":"Kornblit","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106494_bib0063","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haematopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.htct.2026.106494_bib0064","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GvHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2026.106494_bib0065","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41409-024-02245-y","article-title":"Overlap chronic GvHD is associated with adverse survival outcomes compared to classic chronic GvHD","volume":"59","author":"Gorfinkel","year":"2024","journal-title":"Bone Marrow Transpl"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926002415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926002415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:39Z","timestamp":1791475539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137926002415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2531137926002415"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2026.106494","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylaxis of graft-versus-host-disease: Systematic evidence-based recommendations of the Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and the Brazilian society of cellular therapy and bone marrow transplantation (SBTMO)","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2026.106494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}],"article-number":"106494"}}